Oramed Granted Patent in Hong Kong for Oral Administration of Insulin
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Intellectual Property Department of Hong Kong has granted the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins."
Established in 2006, Oramed's Protein Oral Delivery (PODT) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 1 diabetes (T1DM) and type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral GLP-1 analog capsule (ORMD-0901). The company's corporate and R&D headquarters are based in Jerusalem.